Peptide side effects are 'easily countered' — is that true?

What did @.tatteredwizard actually say?

The creator claims that MK-677's two main side effects, elevated blood glucose and water retention, can be "easily countered." For blood glucose, they recommend berberine starting at 500 mg daily and scaling up to 1,500 mg, with metformin (sourced from a telehealth referral link) as a backup at 500 to 1,000 mg daily if berberine falls short. For water retention, they suggest drinking 4 to 6 liters of water per day, referencing that "pharmaceutical growth hormone combines its formulations with some diuretics" while warning against self-dosing diuretics.

To be clear about what this video is: a TikTok creator recommending a specific supplement dosing protocol and directing viewers to a specific telehealth provider to obtain a prescription medication, all in the context of using MK-677, an unapproved investigational compound not cleared by the FDA for any indication.

Does the science back this up?

Partially. Berberine does have real evidence behind its glucose-lowering effects, and MK-677 does measurably elevate blood glucose and cause fluid retention. But the framing that these risks are "easily countered" glosses over what the clinical literature actually shows about MK-677's metabolic profile.

MK-677 (ibutamoren) is a ghrelin receptor agonist that stimulates growth hormone and IGF-1 secretion. Several studies have confirmed it raises fasting glucose and reduces insulin sensitivity. Nass et al. (2008, Annals of Internal Medicine) found that MK-677 in older adults increased fasting blood glucose and HbA1c over 12 months, and the study actually flagged these as clinically significant concerns, not minor inconveniences. On berberine, Yin et al. (2008, Metabolism) demonstrated meaningful HbA1c and fasting glucose reductions in type 2 diabetic patients, comparable in that study to metformin. That's real data. But applying it as a prophylactic protocol alongside an unapproved secretagogue is a different question entirely, and one no randomized trial has addressed.

What did they get wrong (or right)?

They got the basic pharmacology right. MK-677 does raise blood glucose through GH-mediated insulin resistance, and berberine does activate AMPK pathways that improve glucose uptake. Credit where it is due. But several specific claims deserve pushback.

First, the assertion that drinking more water reduces water retention from GH elevation is largely backwards. GH and IGF-1 promote sodium and water reabsorption at the renal level. Drinking additional water does not reverse this mechanism in any meaningful way. No clinical evidence supports the 4 to 6 liter water recommendation as a treatment for GH-induced edema.

Second, the recommendation to bring in metformin if berberine "is not enough" is presented casually, as if adjusting a prescription glucose-lowering medication around an unapproved compound is a routine optimization choice. Metformin carries real contraindications, including renal impairment, and combining it with an insulin-sensitizing supplement like berberine raises additive hypoglycemia risk. Arranging a prescription through a referral link without that context is not a safety protocol.

Third, the target fasting glucose range of 70 to 85 mg/dL is presented as a precise optimization goal, but this is not a clinically established therapeutic target for healthy adults using secretagogues. It is a number borrowed from longevity optimization discourse, not endocrinology guidelines.

What should you actually know?

MK-677 is not an approved drug. It has been studied in clinical trials, but it has not cleared FDA approval for any condition, which means there is no established safe dose, no regulated manufacturing standard for products sold online, and no long-term safety data in healthy adults using it for body composition purposes.

The metabolic concerns are not trivial. Nass et al. (2008) observed that the glucose elevations associated with MK-677 were significant enough that the authors discussed whether the compound's benefits in older adults outweighed cardiometabolic risk. In a healthy young person without diabetes, adding a glucose-lowering drug stack to manage the side effects of an unapproved compound is not mitigation. It is layering one uncontrolled intervention on top of another.

If you are working with a licensed clinician who has reviewed your metabolic labs and is monitoring you, the conversation about secretagogues and glucose management belongs there, not in a 60-second TikTok. The creator's recommendation to seek prescriptions through a specific telehealth referral link does not substitute for that oversight.